Physician profile
Deborah M Johnson
NPI 1902809692
$3,228.62
in general payments reported to CMS, 2019-2025
33 companies · $18.36 in 2025
The $18.36 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,850 · 2020: $369 · 2021: $426 · 2022: $526 · 2024: $38.28 · 2025: $18.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $481.38 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $462.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $305.10 | 2019-2022 | |
| Amgen INC. | $281.07 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $187.66 | 2019-2022 | |
| Celgene Corporation | $165.54 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $140.49 | 2020-2022 | |
| Lilly USA, LLC | $135.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $130.37 | 2022 | |
| Valeritas, INC. | $120.34 | 2019 | |
| Eisai INC. | $96.94 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.56 | 2019-2020 | |
| Tesaro, INC. | $70.33 | 2019 | |
| Pfizer INC. | $66.72 | 2019-2022 | |
| Puma Biotechnology, INC. | $53.02 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $50.51 | 2019 | |
| Incyte Corporation | $40.57 | 2019 | |
| Gilead Sciences, INC. | $38.28 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.85 | 2019-2020 | |
| Daiichi Sankyo INC. | $33.48 | 2019-2020 | |
| Astellas Pharma US INC | $30.27 | 2019 | |
| Genentech USA, INC. | $25.29 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $24.57 | 2021 | |
| Seagen INC. | $23.43 | 2021 | |
| Genmab U.S., INC. | $20.54 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.48 | 2021 | |
| Genzyme Corporation | $18.36 | 2025 | |
| Exelixis INC. | $18.31 | 2019 | |
| Janssen Biotech, INC. | $15.40 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 | |
| Pharmaessentia USA Corporation | $14.69 | 2022 | |
| Blueprint Medicines Corporation | $13.86 | 2020 | |
| Clovis Oncology, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.